Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables - Net: 2009-2025

Historic Receivables - Net for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to $26.6 million.

  • Gyre Therapeutics' Receivables - Net rose 35.99% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.6 million, marking a year-over-year increase of 35.99%. This contributed to the annual value of $24.0 million for FY2024, which is 54.08% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Receivables - Net is $26.6 million, which was up 5.74% from $25.1 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Receivables - Net ranged from a high of $26.6 million in Q3 2025 and a low of $564,000 during Q1 2022.
  • Its 3-year average for Receivables - Net is $19.1 million, with a median of $19.5 million in 2024.
  • Its Receivables - Net has fluctuated over the past 5 years, first tumbled by 45.13% in 2021, then skyrocketed by 842.57% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Receivables - Net (Quarterly) stood at $1.8 million in 2021, then surged by 842.57% to $17.1 million in 2022, then fell by 9.24% to $15.6 million in 2023, then spiked by 54.08% to $24.0 million in 2024, then surged by 35.99% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $25.1 million for Q2 2025, and $22.3 million during Q1 2025.